Business Context and Reporting Period
This Form 8-K is a current report filed by Aeglea Biotherapeutics, Inc. (not Spyre Therapeutics, Inc.) on November 12, 2021. The filing discloses a corporate governance event regarding the appointment of a new director.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on personnel changes and associated compensation.
Material Changes
On November 12, 2021, the Board of Directors appointed Hunter Smith as a Class I director and a member of the Audit Committee, effective immediately. Mr. Smith brings over 25 years of global finance and management experience, including prior roles as CFO at Rhythm Pharmaceuticals, Inc. and Celgene Corporation.
Compensation and Governance Details
- Director Retainer: Mr. Smith will receive a pro rata portion of the $40,000 annual director retainer and a pro rata portion of the $7,500 annual Audit Committee retainer for the remainder of the year.
- Stock Option Grant: The Board granted Mr. Smith an option to purchase 60,000 shares of common stock. The exercise price equals the closing sale price on November 12, 2021. The option vests monthly over three years, contingent on continued service.
- Indemnification: The Company entered into its standard form of indemnification agreement with Mr. Smith.
Investor Verification Checklist
- Verify the closing stock price of Aeglea Biotherapeutics (AGLE) on November 12, 2021, to determine the exercise price of the 60,000 share option grant.
- Review the Company's existing compensation policy for non-employee directors to confirm the pro rata calculation for the retainer fees.
- Confirm the vesting schedule details (monthly over three years) in the definitive stock option agreement.
- Check for any subsequent filings regarding Mr. Smith's continued service or changes to the Audit Committee composition.